摘要
目的探讨2型糖尿病(T2DM)合并宫颈癌患者肿瘤标志物及病理特征变化的意义。方法随机抽取我院2013年1月至2014年1月收治的经病理确诊的T2DM合并宫颈癌患者,非糖尿病性宫颈癌患者各120例,同期无糖尿病史,无宫颈病变的120例健康女性为对照组。比较分析宫颈癌组病理特征变化情况及各组CEA,CA125,鳞状细胞癌抗原(SCC)水平。结果宫颈癌组CA125、SCC较对照组显著升高(P<0.05);T2DM合并宫颈癌组较非糖尿病性宫颈癌组SCC升高,但差异无统计学意义(P>0.05);T2DM合并宫颈癌患者随病理分期进展SCC水平逐渐增加(P<0.05);3组间CEA水平无明显变化(P>0.05)。T2DM合并宫颈癌组患者在病理分期、盆腔淋巴结转移方面与非糖尿病性宫颈癌组比较的差异均有统计学意义(P=0.000)。结论 T2DM合并宫颈癌患者肿瘤病理分期较晚,多有局部淋巴结远处转移,预后不良。动态观察SCC水平有助于判定疾病的进展程度。
Objective To investigate the significance of the changes of tumor markers and pathological characteristics in the cervical cancer patients complicated with type 2 diabetes mellitus （T2DM）. Methods In total, 120 cervical cancer patients complicated with T2DM who had been confirmed pathologically in Fujian Provincial Cancer Hospital from January 2013 to Janu- ary 2014 were chosen in this study. We analyzed the clinicopathological features in eervial cancer patients and the serum CEA, CA125 and SCC level in all the groups. Results The levels of serum CA125 and SCC in cervical cancer group were significantly higher than the control group. The serum SCC level increased in type 2 diabetes compared with non-diabetic group with cervical cancer, but there＇s no statistical significance （P〉0.05）. T2DM with cervical cancer patients with pathological staging progress SCC level gradually increased （P〈0.05）. Moreover, the clinical stage and the proportion of pelvic lymph node metastasis in T2DM patients were higher than that in non-diabetic patients （P= 0. 000）. No significant difference were observed between both groups in terms of serum CEA level and histological type （P〉0.05）. Conclusion Cervical cancer patients with T2DM had a higher proportion of the clinical stage and pelvic lymph node metastasis than non-diabetic patients, which suggested poor prognosis in the cervical cancer patients complicated with T2DM. Dynamic observation of SCC level will help determine the pro- gression of disease.
出处
《福建医药杂志》
CAS
2015年第3期70-72,共3页
Fujian Medical Journal
关键词
2型糖尿病
子宫肿瘤
肿瘤标志物
type 2 diabetes mellitus
cervical cancer
tumor markers
